

This is evidence-based medicine category paper and therefore most of the required statements are not applicable. Please find below the statement of the corresponding author 'Mark Nuijten' for each of the required statements.

CONFLICT-OF-INTEREST STATEMENT

A conflict-of-interest statement is required for all article and study types. In the interests of transparency and helping reviewers to assess any potential bias in a study's design, interpretation of its results or presentation of its scientific/medical content, the Baishideng Publishing Group (BPG) requires all authors of each paper to declare any conflicting interests (including but not limited to commercial, personal, political, intellectual, or religious interests) in the title page that are related to the work submitted for consideration of publication. In addition, reviewers are required to indicate any potential conflicting interests they might have related to any particular paper they are asked to review, and a copy of signed statement should be provided to the BPG in PDF format.

Declaration of interest

C. (Caroline) E. Visser, MD, PhD, Clinical Microbiologist AMC, Amsterdam, the Netherlands; K. (Ken) Redekop, PhD, Clinical Epidemiologist (iMTA), BMG EUR, Rotterdam, the Netherlands; Prof. E. (Eric) Claassen,, PhD, Immunologist VU, Amsterdam and EUR, Rotterdam, the Netherlands and Dr. (Mark) Nuijten, MD, PhD, Ars Accessus Medica, the Netherlands, have no relationships, conditions or circumstances that present a potential conflict of interest to this study.

M. (Marja) H. Pronk, MD, Europe-ExPro, Munich, Germany, has initiated the expert procedure.

J. (Josbert) J. Keller, MD, PhD, Gastro-enterologist, HAGA teaching hospital, Den Haag, the Netherlands is member of the physician's advisory board of Rebiotix and Astellas Pharma.

Prof. P. (Peter) Speelman, MD, PhD, emeritus professor Internal medicine and infectious diseases AMC, Amsterdam, the Netherlands is member of the advisory board of Astellas Pharma.

For this expert procedure unrestricted grants are received from Astellas Pharma B.V. and Danone Research.

Mark Nuijten: This paper has declaration of interest (see above)

In addition on behalf of the authors, I declare that none of the authors has any conflict of interest to mention related to the content of the paper.

Date *3 - march 2015*

Signature

Mark Nuijten